(Press-News.org)
“[...] CMS121 applicability could be expanded from a geroneuroprotector drug to a metabolic drug [...]”
BUFFALO, NY- April 9, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 6, entitled, “CMS121: a novel approach to mitigate aging-related obesity and metabolic dysfunction.”
Modulated by differences in genetic and environmental factors, laboratory mice often show progressive weight gain, eventually leading to obesity and metabolic dyshomeostasis. The geroneuroprotector CMS121 has a positive effect on energy metabolism in a mouse model of type 2 diabetes. In this new study, researchers Alcir L. Dafre, Saadia Zahid, Jessica Jorge Probst, Antonio Currais, Jingting Yu, David Schubert, and Pamela Maher from Salk Institute for Biological Studies, National University of Sciences and Technology (NUST) and Federal University of Santa Catarina investigated the potential of CMS121 to counteract the metabolic changes observed during the ageing process of wild type mice.
“This comprehensive analysis aimed to further understand how CMS121 influences the metabolic landscape, paving the way for potential therapeutic applications beyond its established geroneuroprotective benefits.”
Control or CMS121-containing diets were supplied ad libitum for 6 months, and mice were sacrificed at the age of 7 months. Blood, adipose tissue, and liver were analyzed for glucose, lipids, and protein markers of energy metabolism. The CMS121 diet induced a 40% decrease in body weight gain and improved both glucose and lipid indexes. Lower levels of hepatic caspase 1, caspase 3, and NOX4 were observed with CMS121 indicating a lower liver inflammatory status. Adipose tissue from CMS121-treated mice showed increased levels of the transcription factors Nrf1 and TFAM, as well as markers of mitochondrial electron transport complexes, levels of GLUT4 and a higher resting metabolic rate. Metabolomic analysis revealed elevated plasma concentrations of short chain acylcarnitines and butyrate metabolites in mice treated with CMS121.
“The diminished de novo lipogenesis, which is associated with increased acetyl-CoA, acylcarnitine, and butyrate metabolite levels, could contribute to safeguarding not only the peripheral system but also the aging brain. By mimicking the effects of ketogenic diets, CMS121 holds promise for metabolic diseases such as obesity and diabetes, since these diets are hard to follow over the long term.”
Read the full paper: DOI: https://doi.org/10.18632/aging.205673
Corresponding Authors: Pamela Maher, Alcir L. Dafre
Corresponding Emails: pmaher@salk.edu, alcir.dafre@ufsc.br
Keywords: obesity, diabetes, geroneuroprotection, metabolic disorders, ketogenic diet
Click here to sign up for free Altmetric alerts about this article.
About Aging:
Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer’s diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases.
Aging is indexed by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed Central, Web of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
Please visit our website at www.Aging-US.com and connect with us:
Facebook
X, formerly Twitter
Instagram
YouTube
LinkedIn
Reddit
Pinterest
Spotify, and available wherever you listen to podcasts
Click here to subscribe to Aging publication updates.
For media inquiries, please contact media@impactjournals.com.
Aging (Aging-US) Journal Office
6666 E. Quaker Str., Suite 1B
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 1
###
END
About 90% of deaths from cancer are a result of metastasis — that is, from cancer’s ability to spread from an initial primary tumor to seed new tumors throughout the body, often in the lungs, liver, and brain.
And metastasis relies on cancer cells’ ability to adapt to different tissue environments throughout the body by gaining improper access to a variety of playbooks stored in our genetic code — including gene programs that are generally available only during early stages of human development.
Today, researchers at Memorial Sloan Kettering Cancer Center (MSK) are using innovative approaches like single-cell sequencing technology ...
Vancouver, BC – The Canadian Neuromodulation Society and the International Neuromodulation Society (INS) are delighted to announce a public education event, "Understanding Neuromodulation of the Brain and Spinal Cord”.
This complimentary event is scheduled to take place at the Vancouver Convention Centre, East Building, on Saturday, May 11, from 13:30 to 18:00, during the 16th INS World Congress.
Aimed at patients, their families, and friends dealing with conditions such as chronic pain, Parkinson’s disease, and tremor, this event is ...
SAN ANTONIO — April 9, 2024 — Southwest Research Institute has invested in new space robotics capabilities to help the space industry pave the way for in-space servicing, assembly and manufacturing (ISAM) capabilities. SwRI’s Intelligent Systems Division will demonstrate new ISAM-focused research at the 38th Space Symposium, April 8-11, in Colorado Springs. Visit SwRI at Booth #237.
“SwRI is developing solutions to leverage Earth-based industrial robotics with advanced automation and simulation so we can help clients develop new capabilities for the complex conditions ...
April 9, 2024, Cleveland: New findings from Cleveland Clinic and Tufts University researchers show high blood levels of TMAO (trimethylamine N-oxide) predicts future risk of developing chronic kidney disease over time.
The findings build on more than a decade of research spearheaded by Stanley Hazen, M.D., Ph.D., and a team related to the gut microbiome’s role in cardiovascular health and disease, including the adverse effects of TMAO, a byproduct formed by the gut bacteria from nutrients abundant in red meat, eggs and other animal source foods.
The study, published in the Journal of the American Society of Nephrology, was a collaboration ...
New Orleans, LA – Ochsner Health is proud to bring an advancement in the treatment of heart rhythm disorders to the New Orleans and Gulf South region utilizing a new cardiac ablation procedure, the FARAPULSE™ Pulsed Field Ablation System. The innovative procedure was performed at the John Ochsner Heart & Vascular Institute, a frontrunner in cardiology that continues to set the standard for cardiovascular care through its commitment to pioneering breakthrough therapies.
With the estimated number of individuals affected by atrial fibrillation predicted to rise to 12.1 million in the United States by 2030 according to the CDC, the introduction of this new treatment ...
Genetic studies of diseases map segments of the genome driving disease. But to understand how those changes contribute to disease progression, it is important to understand how they may alter gene regulation of disease genes in cell populations assumed to be driving disease. “Enhancer-gene maps” link genomic regulatory regions to genes and are essential for understanding disease. But constructing them poses challenges due to limitations in current experimental methods, that make it difficult to apply the technique to rare cell populations and genes that ...
We all lose our car keys or our glasses from time to time. Most people would be correct to laugh it off as a normal part of aging. But for others, cognitive decline may start as a worrying but clinically unnoticeable step toward cognitive impairment, be it relatively mild or as severe as Alzheimer’s disease.
The vast complexity of the human brain makes early diagnosis of cognitive decline difficult to achieve, which has potentially important implications for treatment and prevention. This is especially true ...
A clinical trial led by Weill Cornell Medicine investigators showed that a nasal spray that patients administer at home, without a physician, successfully and safely treated recurrent episodes of a condition that causes rapid abnormal heart rhythms. The study, published March 25 in the Journal of the American College of Cardiology, provides real-world evidence that a wide range of patients can safely and effectively use the experimental drug, called etripamil, to treat recurrent paroxysmal supraventricular ...
In the last decade, the emergence of a massive expanse of Sargassum, the Great Atlantic Sargassum Belt, has wreaked havoc on ecosystems and economies throughout the Caribbean. Conversely, this stinky brown seaweed provides vital habitats for marine life including loggerhead sea turtles.
One of the worst invasions of Sargassum in recent history, especially for Florida, occurred in 2022 and potential impacts this year are yet to be determined. Decomposing Sargassum produces hydrogen sulfide and ammonia, which can result in potential human and environmental health impacts. Once Sargassum deluges beaches, removing, disposing and repurposing the seaweed presents many logistical ...
URBANA, Ill. — In the quest to optimize crop productivity across environments, soybean breeders test new cultivars in multiple locations each year. The best-performing cultivars across these locations are selected for further breeding and eventual commercialization. However, a new study from the University of Illinois Urbana-Champaign suggests current soybean testing locations may not be delivering breeders the biggest bang for their buck.
“We met with most of the soybean breeders in public research universities across the Midwest and asked where they set up their trials over the last 30 to 40 years,” said Nicolas Martin, ...
